Emerging Sexual Pharmacology
Identifying pharmacologic treatments for female sexual disorders is an active area of clinical research. Some agents of interest are listed below:
- Libigel®
- Gel formulation of testosterone that is in phase III clinical and safety trials for the treatment of HSDD
- DHEA
- Vaginal suppositories under evaluation in phase III clinical trials for the treatment of vaginal atrophy in postmenopausal women
The following journals are excellent sources for clinical research and emerging trends in female sexual health and management of female sexual dysfunctions: